“…Among these candidates, only physostigmine, an acetylcholinesterase inhibitor, is clinically used and can antagonize opiate-induced respiratory depression (Weinstock et al, 1980;Weinstock et al, 1981;Willette et al, 1986;Snir-Mor et al 1983;Berkenbosch et al, 1994). Acetylcholine (ACh) is an excitatory neurotransmitter in central respiratory control (Murakoshi et al, 1985;Monteau et al, 1990;Burton et al 1995;Shao and Feldman, 2000, 2001, 2002Sakuraba et al 2003), including central chemosensitivity (Monteau et al, 1990;Burton et al 1997;Eugenin and Nicholls, 1997;Eugenin et al, 2001;Okada et al, 2001;Sakuraba et al 2005) and opiates can inhibit the release of ACh from neurons in the central nervous system (Jhamandas et al, 1971;Domino and Wilson, 1973;Zsilla et al, 1977). However, physostigmine has numerous disadvantages, e.g.…”